What records are connected here?
- Evidence lanes
- 2
- Source years
- 5
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials3,4,5Evidence: Large human trialsInfections
Also called Zyesami3
Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP), a 28-amino-acid human peptide, recorded in FDA’s substance registry.3 In TESICO, a randomized, placebo-controlled trial of 461 adults in intensive care or on breathing support for COVID-19 respiratory failure, aviptadil did not improve recovery or survival at 90 days.4 No FDA approval is reported in the sources reviewed here. Aviptadil does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.3,5,7
| What it is | A synthetic 28-amino-acid peptide with the sequence of human vasoactive intestinal peptide, recorded as aviptadil and, in its acetate form, under the name Zyesami in FDA’s substance registry.3 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list aviptadil.3,5 |
| Human evidence | One large randomized, placebo-controlled trial (TESICO) in 461 adults with COVID-19 respiratory failure, which found no benefit, published in 2023.4 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Aviptadil is a synthetic peptide of 28 amino acids matching human vasoactive intestinal peptide. FDA’s substance registry records it as aviptadil and VIP, and its acetate salt under the name Zyesami.3
The TESICO investigators describe aviptadil as a lung-protective neuropeptide and tested whether it could improve recovery from COVID-19 respiratory failure.4
TESICO randomized adults hospitalized with COVID-19 respiratory failure at 28 U.S. sites; 461 received at least part of their assigned aviptadil or placebo, and 94% were in intensive care at the start.4
At day 90, aviptadil did not improve the main recovery outcome. Deaths up to day 90 were 38% with aviptadil and 36% with placebo, and the trial was stopped early for futility.4
ClinicalTrials.gov lists TESICO (NCT04843761) and a second Phase 3 COVID-19 trial (NCT06729606) as completed in their October 2025 records.1,2
Evidence-strength label: Large randomized human trials. How this label is assigned
None of the sources reviewed here reports an approval of aviptadil by FDA.3,5
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list aviptadil.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Aviptadil is not among them.6,7
Whether it helps in any other condition: the large trial cited here studied only COVID-19 respiratory failure and found no benefit.4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Aviptadil: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Aviptadil are a bounded selection, not every registration or paper about Aviptadil. For the years before Aviptadil was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Aviptadil as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Aviptadil in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
Not FDA-approved; studied in clinical trials. In a randomized, placebo-controlled trial of 461 adults with COVID-19 respiratory failure, aviptadil did not improve recovery or survival. Aviptadil is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
Not FDA-approved; studied in clinical trials. In a randomized, placebo-controlled trial of 461 adults with COVID-19 respiratory failure, aviptadil did not improve recovery or survival. Aviptadil is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date September 25, 2026
Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage?↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage?↗Source date September 25, 2026Literature metadata · added November 16, 2026
Molecular Interactions of Zyesami with the SARS-CoV-2 nsp10/nsp16 Protein Complex.↗Source date January 27, 2026Literature metadata · added November 16, 2026
Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.↗Source date December 12, 2025PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
2 of 2 selected trial records include at least one phase value; 2 of 2 include a status value in the retained structured contract.
7 of 7 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT04843761 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was aviptadil.
PeptideScanner retained ClinicalTrials.gov record NCT06729606 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-09, and PeptideScanner's reviewed identity mapping was aviptadil.
PubMed lists PMID 11566015 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Review, with publication-date metadata of 2001-04 (month precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
7 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span January 1, 2019 to September 25, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 41368453 in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine as Editorial, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35975856 in Combinatorial chemistry & high throughput screening as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023 (year precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41368449 in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine as Journal Article, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04843761 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was aviptadil.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06729606 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-09, and PeptideScanner's reviewed identity mapping was aviptadil.↗
Literature metadata
PubMed lists PMID 37774815 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2023-09-27 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 34846667 in Environmental science and pollution research international as Journal Article, Review, with publication-date metadata of 2021-11-30 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 11566015 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Review, with publication-date metadata of 2001-04 (month precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24176753 in Journal of pharmaceutical and biomedical analysis as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-10-05 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
The Lancet Respiratory Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026